HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ZITHROMAX® safely and effectively. See full prescribing information for ZITHROMAX.

ZITHROMAX (azithromycin) 250 mg and 500 mg Tablets and Oral Suspension

INDICATIONS AND USAGE
ZITHROMAX is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria:
- Acute bacterial exacerbations of chronic bronchitis in adults (1.1)
- Acute bacterial sinusitis in adults (1.1)
- Uncomplicated skin and skin structure infections in adults (1.1)
- Urethritis and cervicitis in adults (1.1)
- Genital ulcer disease in men (1.1)
- Acute otitis media in pediatric patients (1.2)
- Community-acquired pneumonia in adults and pediatric patients (1.1, 1.2)
- Pharyngitis/tonsillitis in adults and pediatric patients (1.1, 1.2)

Limitation of Use:
Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors. (1.3)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX (azithromycin) and other antibacterial drugs, ZITHROMAX (azithromycin) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.4)

DOSAGE AND ADMINISTRATION

Adult Patients (2.1)

<table>
<thead>
<tr>
<th>Infection</th>
<th>Recommended Dose/Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community-acquired pneumonia (mild severity)</td>
<td>500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.</td>
</tr>
<tr>
<td>Pharyngitis/tonsillitis (second-line therapy)</td>
<td></td>
</tr>
<tr>
<td>Skin/skin structure (uncomplicated)</td>
<td></td>
</tr>
<tr>
<td>Acute bacterial exacerbations of chronic bronchitis (mild to moderate)</td>
<td>500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days.</td>
</tr>
<tr>
<td>Acute bacterial sinusitis</td>
<td>500 mg once daily for 3 days.</td>
</tr>
<tr>
<td>Genital ulcer disease (chancroid)</td>
<td></td>
</tr>
<tr>
<td>Non-gonococcal urethritis and cervicitis</td>
<td>One single 1 gram dose.</td>
</tr>
<tr>
<td>Gonococcal urethritis and cervicitis</td>
<td>One single 2 gram dose.</td>
</tr>
</tbody>
</table>

Pediatric Patients (2.2)

<table>
<thead>
<tr>
<th>Infection</th>
<th>Recommended Dose/Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute otitis media</td>
<td>30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5.</td>
</tr>
<tr>
<td>Acute bacterial sinusitis</td>
<td>10 mg/kg once daily for 3 days.</td>
</tr>
<tr>
<td>Community-acquired pneumonia</td>
<td>10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5.</td>
</tr>
<tr>
<td>Pharyngitis/tonsillitis</td>
<td>12 mg/kg once daily for 5 days.</td>
</tr>
</tbody>
</table>

DOSAGE FORMS AND STRENGTHS

- ZITHROMAX tablets 250 mg and 500 mg (3)
ZITHROMAX for oral suspension 100 mg/5 mL and 200 mg/5 mL (3)

- CONTRAINDICATIONS
  - Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. (4.1)
  - Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (4.2)

- WARNINGS AND PRECAUTIONS
  - Serious (including fatal) allergic and skin reactions: Discontinue ZITHROMAX if reaction occurs. (5.1)
  - Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported; Discontinue ZITHROMAX immediately if signs and symptoms of hepatitis occur. (5.2)
  - Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (5.3)
  - Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarhythmic conditions, and with other drugs that prolong the QT interval. (5.4)
  - Clostridium difficile-Associated Diarrhea: Evaluate patients if diarrhea occurs. (5.5)
  - ZITHROMAX may exacerbate muscle weakness in persons with myasthenia gravis. (5.6)

- ADVERSE REACTIONS
  Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

- DRUG INTERACTIONS
  - Nelfinavir: Close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (7.1)
  - Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (7.2)

- USE IN SPECIFIC POPULATIONS
  - Pediatric use: Safety and effectiveness in the treatment of patients under 6 months of age have not been established. (8.4)
  - Geriatric use: Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. (8.5)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 8/2018
5.4 QT Prolongation
5.5 Clostridium difficile-Associated Diarrhea (CDAD)
5.6 Exacerbation of Myasthenia Gravis
5.7 Use in Sexually Transmitted Infections
5.8 Development of Drug-Resistant Bacteria

6 ADVERSE REACTIONS
   6.1 Clinical Trials Experience
   6.2 Postmarketing Experience
   6.3 Laboratory Abnormalities

7 DRUG INTERACTIONS
   7.1 Nelfinavir
   7.2 Warfarin
   7.3 Potential Drug-Drug Interactions with Macrolides

8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.3 Nursing Mothers
   8.4 Pediatric Use
   8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
   12.2 Pharmacodynamics
   12.3 Pharmacokinetics
   12.4 Microbiology

13 NONCLINICAL TOXICOLOGY
   13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
   13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES
   14.1 Adult Patients
   14.2 Pediatric Patients

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION
   General Patient Counseling
   See FDA-approved Patient Labeling

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

ZITHROMAX (azithromycin) is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2)]

1.1 Adult Patients
   • Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
   • Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.
Community-acquired pneumonia due to *Chlamydophila pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae*, or *Streptococcus pneumoniae* in patients appropriate for oral therapy.

Pharyngitis/tonsillitis caused by *Streptococcus pyogenes* as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to *Staphylococcus aureus*, *Streptococcus pyogenes*, or *Streptococcus agalactiae*.

Urethritis and cervicitis due to *Chlamydia trachomatis* or *Neisseria gonorrhoeae*.

Genital ulcer disease in men due to *Haemophilus ducreyi* (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.

1.2 Pediatric Patients

[see Use in Specific Populations (8.4) and Clinical Studies (14.2)]

- Acute otitis media (*>6 months of age*) caused by *Haemophilus influenzae*, *Moraxella catarrhalis*, or *Streptococcus pneumoniae*.
- Community-acquired pneumonia (*>6 months of age*) due to *Chlamydophila pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae*, or *Streptococcus pneumoniae* in patients appropriate for oral therapy.
- Pharyngitis/tonsillitis (*>2 years of age*) caused by *Streptococcus pyogenes* as an alternative to first-line therapy in individuals who cannot use first-line therapy.

1.3 Limitations of Use

Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:

- patients with cystic fibrosis,
- patients with nosocomial infections,
- patients with known or suspected bacteremia,
- patients requiring hospitalization,
- elderly or debilitated patients, or
- patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia).

1.4 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX (azithromycin) and other antibacterial drugs, ZITHROMAX (azithromycin) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Adult Patients

[see Indications and Usage (1.1) and Clinical Pharmacology (12.3)]

<table>
<thead>
<tr>
<th>Infection*</th>
<th>Recommended Dose/Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community-acquired pneumonia</td>
<td>500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5</td>
</tr>
</tbody>
</table>
| Pharyngitis/tonsillitis (second-line therapy) | }
Skin/skin structure (uncomplicated)

Acute bacterial exacerbations of chronic obstructive pulmonary disease
500 mg once daily for 3 days
OR
500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5

Acute bacterial sinusitis
500 mg once daily for 3 days

Genital ulcer disease (chancroid)
One single 1 gram dose

Non-gonococcal urethritis and cervicitis
One single 1 gram dose

Gonococcal urethritis and cervicitis
One single 2 gram dose

* DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1)]

ZITHROMAX tablets can be taken with or without food.

2.2 Pediatric Patients

<table>
<thead>
<tr>
<th>Infection*</th>
<th>Recommended Dose/Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute otitis media</td>
<td>30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5.</td>
</tr>
<tr>
<td>Acute bacterial sinusitis</td>
<td>10 mg/kg once daily for 3 days.</td>
</tr>
<tr>
<td>Community-acquired pneumonia</td>
<td>10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5.</td>
</tr>
<tr>
<td>Pharyngitis/tonsillitis</td>
<td>12 mg/kg once daily for 5 days.</td>
</tr>
</tbody>
</table>

1 see dosing tables below for maximum doses evaluated by indication
* DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.2)]

ZITHROMAX for oral suspension can be taken with or without food.

PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA, ACUTE BACTERIAL SINUSITIS, AND COMMUNITY-ACQUIRED PNEUMONIA
(Age 6 months and above, [see Use in Specific Populations (8.4)])
Based on Body Weight

OTITIS MEDIA AND COMMUNITY-ACQUIRED PNEUMONIA: (5-Day Regimen)*

<table>
<thead>
<tr>
<th>Weight Kg</th>
<th>Lbs.</th>
<th>Day 1</th>
<th>Days 2–5</th>
<th>Day 1</th>
<th>Days 2–5</th>
<th>Total mL per Treatment Course</th>
<th>Total mg per Treatment Course</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>11</td>
<td>2.5 mL; (½ tsp)</td>
<td>1.25 mL; (¼ tsp)</td>
<td>7.5 mL</td>
<td>150 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>22</td>
<td>5 mL; (1 tsp)</td>
<td>2.5 mL; (½ tsp)</td>
<td>15 mL</td>
<td>300 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>44</td>
<td>5 mL; (1 tsp)</td>
<td>2.5 mL; (½ tsp)</td>
<td>15 mL</td>
<td>600 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>66</td>
<td>7.5 mL; (1½ tsp)</td>
<td>3.75 mL; (¾ tsp)</td>
<td>22.5 mL</td>
<td>900 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>88</td>
<td>10 mL; (2 tsp)</td>
<td>5 mL; (1 tsp)</td>
<td>30 mL</td>
<td>1200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 and above</td>
<td>110 and above</td>
<td>12.5 mL; (2½ tsp)</td>
<td>6.25 mL; (1¼ tsp)</td>
<td>37.5 mL</td>
<td>1500 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Effectiveness of the 3-day or 1-day regimen in pediatric patients with community-acquired pneumonia has not
OTITIS MEDIA AND ACUTE BACTERIAL SINUSITIS: (3-Day Regimen)*

<table>
<thead>
<tr>
<th>Weight Kg</th>
<th>Lbs.</th>
<th>100 mg/5 mL Days 1–3</th>
<th>200 mg/5 mL Days 1–3</th>
<th>Total mL per Treatment Course</th>
<th>Total mg per Treatment Course</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>11</td>
<td>2.5 mL; (1/2 tsp)</td>
<td></td>
<td>7.5 mL</td>
<td>150 mg</td>
</tr>
<tr>
<td>10</td>
<td>22</td>
<td>5 mL; (1 tsp)</td>
<td></td>
<td>15 mL</td>
<td>300 mg</td>
</tr>
<tr>
<td>20</td>
<td>44</td>
<td></td>
<td>5 mL (1 tsp)</td>
<td>15 mL</td>
<td>600 mg</td>
</tr>
<tr>
<td>30</td>
<td>66</td>
<td></td>
<td>7.5 mL (1½ tsp)</td>
<td>22.5 mL</td>
<td>900 mg</td>
</tr>
<tr>
<td>40</td>
<td>88</td>
<td></td>
<td>10 mL (2 tsp)</td>
<td>30 mL</td>
<td>1200 mg</td>
</tr>
<tr>
<td>50 and above</td>
<td>110 and above</td>
<td>12.5 mL (2 ½ tsp)</td>
<td>37.5 mL</td>
<td>1500 mg</td>
<td></td>
</tr>
</tbody>
</table>

* Effectiveness of the 5-day or 1-day regimen in pediatric patients with acute bacterial sinusitis has not been established.

OTITIS MEDIA: (1-Day Regimen)

<table>
<thead>
<tr>
<th>Weight Kg</th>
<th>Lbs.</th>
<th>200 mg/5 mL 1-Day Regimen</th>
<th>Total mL per Treatment Course</th>
<th>Total mg per Treatment Course</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>11</td>
<td>3.75 mL;(3/4 tsp)</td>
<td>3.75 mL</td>
<td>150 mg</td>
</tr>
<tr>
<td>10</td>
<td>22</td>
<td>7.5 mL;(1½ tsp)</td>
<td>7.5 mL</td>
<td>300 mg</td>
</tr>
<tr>
<td>20</td>
<td>44</td>
<td>15 mL;(3 tsp)</td>
<td>15 mL</td>
<td>600 mg</td>
</tr>
<tr>
<td>30</td>
<td>66</td>
<td>22.5 mL;(4½ tsp)</td>
<td>22.5 mL</td>
<td>900 mg</td>
</tr>
<tr>
<td>40</td>
<td>88</td>
<td>30 mL;(6 tsp)</td>
<td>30 mL</td>
<td>1200 mg</td>
</tr>
<tr>
<td>50 and above</td>
<td>110 and above</td>
<td>37.5 mL;(7½ tsp)</td>
<td>37.5 mL</td>
<td>1500 mg</td>
</tr>
</tbody>
</table>

The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.

Pharyngitis/Tonsillitis: The recommended dose of ZITHROMAX for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)

PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS
(Age 2 years and above, [see Use in Specific Populations (8.4)])
Based on Body Weight

PHARYNGITIS/TONSILLITIS: (5-Day Regimen)

<table>
<thead>
<tr>
<th>Weight Kg</th>
<th>Lbs.</th>
<th>200 mg/5 mL Day 1–5</th>
<th>Total mL per Treatment Course</th>
<th>Total mg per Treatment Course</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>18</td>
<td>2.5 mL; (1/2 tsp)</td>
<td>12.5 mL</td>
<td>500 mg</td>
</tr>
<tr>
<td>17</td>
<td>37</td>
<td>5 mL; (1 tsp)</td>
<td>25 mL</td>
<td>1000 mg</td>
</tr>
<tr>
<td>25</td>
<td>55</td>
<td>7.5 mL; (1½ tsp)</td>
<td>37.5 mL</td>
<td>1500 mg</td>
</tr>
<tr>
<td>33</td>
<td>73</td>
<td>10 mL; (2 tsp)</td>
<td>50 mL</td>
<td>2000 mg</td>
</tr>
<tr>
<td>40</td>
<td>88</td>
<td>12.5 mL; (2 ½ tsp)</td>
<td>62.5 mL</td>
<td>2500 mg</td>
</tr>
</tbody>
</table>
Constituting instructions for ZITHROMAX Oral Suspension 300, 600, 900, 1200 mg bottles. The table below indicates the volume of water to be used for constitution:

<table>
<thead>
<tr>
<th>Amount of water to be added</th>
<th>Total volume after constitution (azithromycin content)</th>
<th>Azithromycin concentration after constitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 mL (300 mg)</td>
<td>15 mL (300 mg)</td>
<td>100 mg/5 mL</td>
</tr>
<tr>
<td>9 mL (600 mg)</td>
<td>15 mL (600 mg)</td>
<td>200 mg/5 mL</td>
</tr>
<tr>
<td>12 mL (900 mg)</td>
<td>22.5 mL (900 mg)</td>
<td>200 mg/5 mL</td>
</tr>
<tr>
<td>15 mL (1200 mg)</td>
<td>30 mL (1200 mg)</td>
<td>200 mg/5 mL</td>
</tr>
</tbody>
</table>

Shake well before each use. Oversized bottle provides shake space. Keep tightly closed.

After mixing, store suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.

3 DOSAGE FORMS AND STRENGTHS

ZITHROMAX 250 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 250 mg of azithromycin. ZITHROMAX 250 mg tablets are engraved with "PFIZER" on one side and "306" on the other, or "Pfizer" on one side and "ZTM 250" on the other. These are packaged in bottles and blister cards of 6 tablets (Z-PAKS®).

ZITHROMAX 500 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 500 mg of azithromycin. ZITHROMAX 500 mg tablets are engraved with "Pfizer" on one side and "ZTM500" on the other. These are packaged in bottles and blister cards of 3 tablets (TRI-PAKSTM).

ZITHROMAX for oral suspension after constitution contains a flavored suspension. ZITHROMAX for oral suspension is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

ZITHROMAX is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug.

4.2 Hepatic Dysfunction

ZITHROMAX is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity

Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported in patients on azithromycin therapy. [see Contraindications (4.1)]

Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of
azithromycin and subsequent prolonged exposure to antigen is presently unknown.

If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that allergic symptoms may reappear when symptomatic therapy has been discontinued.

5.2 Hepatotoxicity
Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.

5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)
Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.

5.4 QT Prolongation
Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:
- patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure
- patients on drugs known to prolong the QT interval
- patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.

Elderly patients may be more susceptible to drug-associated effects on the QT interval.

5.5 Clostridium difficile-Associated Diarrhea (CDAD)
*Clostridium difficile*-associated diarrhea has been reported with use of nearly all antibacterial agents, including ZITHROMAX, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of *C. difficile*.

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

5.6 Exacerbation of Myasthenia Gravis
Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.

5.7 Use in Sexually Transmitted Infections
ZITHROMAX, at the recommended dose, should not be relied upon to treat syphilis. Antibacterial agents used to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis.
and appropriate testing for gonorrhea performed at the time of diagnosis. Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.

5.8 Development of Drug-Resistant Bacteria

Prescribing ZITHROMAX in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug. Potentially serious adverse reactions of angioedema and cholestatic jaundice were reported. Approximately 0.7% of the patients (adults and pediatric patients) from the 5-day multiple-dose clinical trials discontinued ZITHROMAX (azithromycin) therapy because of treatment-related adverse reactions. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related adverse reactions was 0.6%. In clinical trials in pediatric patients given 30 mg/kg, either as a single dose or over 3 days, discontinuation from the trials due to treatment-related adverse reactions was approximately 1%. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. [see Clinical Studies (14.2)]

Adults

Multiple-dose regimens: Overall, the most common treatment-related adverse reactions in adult patients receiving multiple-dose regimens of ZITHROMAX were related to the gastrointestinal system with diarrhea/loose stools (4 to 5%), nausea (3%), and abdominal pain (2 to 3%) being the most frequently reported.

No other adverse reactions occurred in patients on the multiple-dose regimens of ZITHROMAX with a frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or less included the following:

Cardiovascular: Palpitations, chest pain.

Gastrointestinal: Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice.

Genitourinary: Monilia, vaginitis, and nephritis.

Nervous System: Dizziness, headache, vertigo, and somnolence.

General: Fatigue.

Allergic: Rash, pruritus, photosensitivity, and angioedema.

Single 1-gram dose regimen:

Overall, the most common adverse reactions in patients receiving a single-dose regimen of 1 gram of ZITHROMAX were related to the gastrointestinal system and were more frequently reported than in patients receiving the multiple-dose regimen.

Adverse reactions that occurred in patients on the single 1-gram dosing regimen of ZITHROMAX with a frequency of 1% or greater included diarrhea/loose stools (7%), nausea (5%), abdominal pain (5%), vomiting (2%), dyspepsia (1%), and vaginitis (1%).
Single 2-gram dose regimen:

Overall, the most common adverse reactions in patients receiving a single 2-gram dose of ZITHROMAX were related to the gastrointestinal system. Adverse reactions that occurred in patients in this study with a frequency of 1% or greater included nausea (18%), diarrhea/loose stools (14%), vomiting (7%), abdominal pain (7%), vaginitis (2%), dyspepsia (1%), and dizziness (1%). The majority of these complaints were mild in nature.

**Pediatric Patients**

Single and Multiple-dose regimens: The types of adverse reactions in pediatric patients were comparable to those seen in adults, with different incidence rates for the dosage regimens recommended in pediatric patients.

**Acute Otitis Media:** For the recommended total dosage regimen of 30 mg/kg, the most frequent adverse reactions (≥1%) attributed to treatment were diarrhea, abdominal pain, vomiting, nausea, and rash. [see Dosage and Administration (2) and Clinical Studies (14.2)]

The incidence, based on dosing regimen, is described in the table below:

<table>
<thead>
<tr>
<th>Dosage Regimen</th>
<th>Diarrhea %</th>
<th>Abdominal Pain %</th>
<th>Vomiting %</th>
<th>Nausea %</th>
<th>Rash %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-day</td>
<td>4.3%</td>
<td>1.4%</td>
<td>4.9%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
<tr>
<td>3-day</td>
<td>2.6%</td>
<td>1.7%</td>
<td>2.3%</td>
<td>0.4%</td>
<td>0.6%</td>
</tr>
<tr>
<td>5-day</td>
<td>1.8%</td>
<td>1.2%</td>
<td>1.1%</td>
<td>0.5%</td>
<td>0.4%</td>
</tr>
</tbody>
</table>

**Community-Acquired Pneumonia:** For the recommended dosage regimen of 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5, the most frequent adverse reactions attributed to treatment were diarrhea/loose stools, abdominal pain, vomiting, nausea, and rash.

The incidence is described in the table below:

<table>
<thead>
<tr>
<th>Dosage Regimen</th>
<th>Diarrhea/Loose stools %</th>
<th>Abdominal Pain %</th>
<th>Vomiting %</th>
<th>Nausea %</th>
<th>Rash %</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-day</td>
<td>5.8%</td>
<td>1.9%</td>
<td>1.9%</td>
<td>1.9%</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

**Pharyngitis/Tonsillitis:** For the recommended dosage regimen of 12 mg/kg on Days 1–5, the most frequent adverse reactions attributed to treatment were diarrhea, vomiting, abdominal pain, nausea, and headache.

The incidence is described in the table below:

<table>
<thead>
<tr>
<th>Dosage Regimen</th>
<th>Diarrhea %</th>
<th>Abdominal Pain %</th>
<th>Vomiting %</th>
<th>Nausea %</th>
<th>Rash %</th>
<th>Headache %</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-day</td>
<td>5.4%</td>
<td>3.4%</td>
<td>5.6%</td>
<td>1.8%</td>
<td>0.7%</td>
<td>1.1%</td>
</tr>
</tbody>
</table>

With any of the treatment regimens, no other adverse reactions occurred in pediatric patients treated with ZITHROMAX with a frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or less included the following:

**Cardiovascular:** Chest pain.

**Gastrointestinal:** Dyspepsia, constipation, anorexia, enteritis, flatulence, gastritis, jaundice, loose stools, and oral moniliasis.

**Hematologic and Lymphatic:** Anemia and leukopenia.
Nervous System: Headache (otitis media dosage), hyperkinesia, dizziness, agitation, nervousness, and insomnia.

General: Fever, face edema, fatigue, fungal infection, malaise, and pain.

Allergic: Rash and allergic reaction.

Respiratory: Cough, pharyngitis, pleural effusion, and rhinitis.

Skin and Appendages: Eczema, fungal dermatitis, pruritus, sweating, urticaria, and vesiculobullous rash.

Special Senses: Conjunctivitis.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of azithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include:

Allergic: Arthralgia, edema, urticaria, and angioedema.

Cardiovascular: Arrhythmias including ventricular tachycardia and hypotension. There have been reports of QT prolongation and torsades de pointes.

Gastrointestinal: Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and reports of tongue discoloration.

General: Asthenia, paresthesia, fatigue, malaise, and anaphylaxis.

Genitourinary: Interstitial nephritis and acute renal failure and vaginitis.

Hematopoietic: Thrombocytopenia.

Liver/Biliary: Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure. [see Warnings and Precautions (5.2)]

Nervous System: Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation, and syncope.

Psychiatric: Aggressive reaction and anxiety.

Skin/Appendages: Pruritus serious skin reactions including erythema multiforme, AGEP, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS.

Special Senses: Hearing disturbances including hearing loss, deafness and/or tinnitus, and reports of taste/smell perversion and/or loss.

6.3 Laboratory Abnormalities

Adults:

Clinically significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows: with an incidence of greater than 1%: decreased hemoglobin, hematocrit, lymphocytes, neutrophils, and blood glucose; elevated serum creatine phosphokinase, potassium, ALT, GGT, AST, BUN, creatinine, blood glucose, platelet count, lymphocytes, neutrophils, and eosinophils; with an incidence of less than 1%: leukopenia, neutropenia, decreased sodium, potassium, platelet count, elevated monocytes, basophils, bicarbonate, serum alkaline phosphatase, bilirubin, LDH, and phosphate. The majority of subjects with elevated serum creatinine also had abnormal values at baseline. When follow-up was provided, changes in laboratory tests appeared to be reversible.

In multiple-dose clinical trials involving more than 5000 patients, four patients discontinued therapy
because of treatment-related liver enzyme abnormalities and one because of a renal function abnormality.

**Pediatric Patients:**

One, Three, and Five Day Regimens

Laboratory data collected from comparative clinical trials employing two 3-day regimens (30 mg/kg or 60 mg/kg in divided doses over 3 days), or two 5-day regimens (30 mg/kg or 60 mg/kg in divided doses over 5 days) were similar for regimens of azithromycin and all comparators combined, with most clinically significant laboratory abnormalities occurring at incidences of 1–5%. Laboratory data for patients receiving 30 mg/kg as a single dose were collected in one single center trial. In that trial, an absolute neutrophil count between 500–1500 cells/mm$^3$ was observed in 10/64 patients receiving 30 mg/kg as a single dose, 9/62 patients receiving 30 mg/kg given over 3 days, and 8/63 comparator patients. No patient had an absolute neutrophil count <500 cells/mm$^3$.

In multiple-dose clinical trials involving approximately 4700 pediatric patients, no patients discontinued therapy because of treatment-related laboratory abnormalities.

7 **DRUG INTERACTIONS**

7.1 **Nelfinavir**

Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. [see Adverse Reactions (6)]

7.2 **Warfarin**

Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin. Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.

7.3 Potential Drug-Drug Interactions with Macrolides

Interactions with digoxin or phenytoin have not been reported in clinical trials with azithromycin; however, no specific drug interaction studies have been performed to evaluate potential drug-drug interactions. However, drug interactions have been observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin or phenytoin are used concomitantly with azithromycin careful monitoring of patients is advised.

8 **USE IN SPECIFIC POPULATIONS**

8.1 **Pregnancy**

Teratogenic Effects: Pregnancy Category B: Reproduction studies have been performed in rats and mice at doses up to moderately maternally toxic dose concentrations (i.e., 200 mg/kg/day). These daily doses in rats and mice, based on body surface area, are estimated to be 4 and 2 times, respectively, an adult daily dose of 500 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.
8.3 Nursing Mothers
Azithromycin has been reported to be excreted in human breast milk in small amounts. Caution should be exercised when azithromycin is administered to a nursing woman.

8.4 Pediatric Use
[see Clinical Pharmacology (12.3), Indications and Usage (1.2), and Dosage and Administration (2.2)]
Safety and effectiveness in the treatment of pediatric patients with acute otitis media, acute bacterial sinusitis and community-acquired pneumonia under 6 months of age have not been established. Use of ZITHROMAX for the treatment of acute bacterial sinusitis and community-acquired pneumonia in pediatric patients (6 months of age or greater) is supported by adequate and well-controlled trials in adults

Pharyngitis/Tonsillitis: Safety and effectiveness in the treatment of pediatric patients with pharyngitis/tonsillitis under 2 years of age have not been established.

8.5 Geriatric Use
In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients. [see Warnings and Precautions (5.4)]

10 OVERDOSAGE
Adverse reactions experienced at higher than recommended doses were similar to those seen at normal doses particularly nausea, diarrhea, and vomiting. In the event of overdosage, general symptomatic and supportive measures are indicated as required.

11 DESCRIPTION
ZITHROMAX (azithromycin tablets and azithromycin for oral suspension) contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C38H72N2O12, and its molecular weight is 749.00. Azithromycin has the following structural formula:
Azithromycin, as the dihydrate, is a white crystalline powder with a molecular formula of C38H72N2O12·2H2O and a molecular weight of 785.0.

ZITHROMAX is supplied as tablets containing azithromycin dihydrate equivalent to either 250 mg or 500 mg azithromycin and the following inactive ingredients: dibasic calcium phosphate anhydrous, pregelatinized starch, sodium croscarmellose, magnesium stearate, sodium lauryl sulfate, hypromellose, lactose, titanium dioxide, triacetin, and D&C Red #30 aluminum lake.

ZITHROMAX for oral suspension is supplied in bottles containing azithromycin dihydrate powder equivalent to 300 mg, 600 mg, 900 mg, or 1200 mg azithromycin per bottle and the following inactive ingredients: sucrose; sodium phosphate, tribasic, anhydrous; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and spray dried artificial cherry, creme de vanilla, and banana flavors. After constitution, each 5 mL of suspension contains 100 mg or 200 mg of azithromycin.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Azithromycin is a macrolide antibacterial drug. [see Microbiology (12.4)]

12.2 Pharmacodynamics

Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens (S. pneumoniae and S. aureus). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with azithromycin.

Cardiac Electrophysiology

QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with oral azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.

12.3 Pharmacokinetics
Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 fasted healthy male volunteers, the mean (SD) pharmacokinetic parameters were $\text{AUC}_{0-72}=4.3 \ (1.2) \ \text{mcg-hr/mL}; \ C_{\text{max}}=0.5 \ (0.2) \ \text{mcg/mL}; \ T_{\text{max}}=2.2 \ (0.9) \ \text{hours}$. Two azithromycin 250 mg tablets are bioequivalent to a single 500 mg tablet.

In a two-way crossover study, 12 adult healthy volunteers (6 males, 6 females) received 1500 mg of azithromycin administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2–5) or 3 days (500 mg per day for days 1–3). Due to limited serum samples on day 2 (3-day regimen) and days 2–4 (5-day regimen), the serum concentration-time profile of each subject was fit to a 3-compartment model and the AUC$_{0-\infty}$ for the fitted concentration profile was comparable between the 5-day and 3-day regimens.

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter [mean (SD)]</th>
<th>3-Day Regimen</th>
<th>5-Day Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
<td>Day 3</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (serum, mcg/mL)</td>
<td>0.44 (0.22)</td>
<td>0.54 (0.25)</td>
</tr>
<tr>
<td>Serum AUC$_{0-\infty}$ (mcg-hr/mL)</td>
<td>17.4 (6.2)*</td>
<td></td>
</tr>
<tr>
<td>Serum $T_{1/2}$</td>
<td>71.8 hr</td>
<td></td>
</tr>
</tbody>
</table>

* Total AUC for the entire 3-day and 5-day regimens.

**Absorption**

The absolute bioavailability of azithromycin 250 mg capsules is 38%.

In a two-way crossover study in which 12 healthy subjects received a single 500 mg dose of azithromycin (two 250 mg tablets) with or without a high fat meal, food was shown to increase $C_{\text{max}}$ by 23% but had no effect on AUC.

When azithromycin oral suspension was administered with food to 28 adult healthy male subjects, $C_{\text{max}}$ increased by 56% and AUC was unchanged.

**Distribution**

The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.

The antibacterial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity.

Azithromycin has been shown to penetrate into human tissues, including skin, lung, tonsil, and cervix. Extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of infections in these additional body sites, the clinical significance of these tissue concentration data is unknown.

Following a regimen of 500 mg on the first day and 250 mg daily for 4 days, very low concentrations were noted in cerebrospinal fluid (less than 0.01 mcg/mL) in the presence of noninflamed meninges.

**Metabolism**

*In vitro* and *in vivo* studies to assess the metabolism of azithromycin have not been performed.

**Elimination**

Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hr. The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues. Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered
dose appears as unchanged drug in urine.

**Specific Populations**

**Renal Insufficiency**

Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1.0 g dose of azithromycin (4 × 250 mg capsules), mean $C_{\text{max}}$ and AUC$_{0-120}$ increased by 5.1% and 4.2%, respectively, in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/min) compared to subjects with normal renal function (GFR >80 mL/min). The mean $C_{\text{max}}$ and AUC$_{0-120}$ increased 61% and 35%, respectively, in subjects with severe renal impairment (GFR <10 mL/min) compared to subjects with normal renal function (GFR >80 mL/min).

**Hepatic Insufficiency**

The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established.

**Gender**

There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.

**Geriatric Patients**

Pharmacokinetic parameters in older volunteers (65 to 85 years old) were similar to those in young adults (18 to 40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen. [see Geriatric Use (8.5)]

**Pediatric Patients**

In two clinical studies, azithromycin for oral suspension was dosed at 10 mg/kg on day 1, followed by 5 mg/kg on days 2 through 5 in two groups of pediatric patients (aged 1–5 years and 5–15 years, respectively). The mean pharmacokinetic parameters on day 5 were $C_{\text{max}}=0.216$ mcg/mL, $T_{\text{max}}=1.9$ hr, and AUC$_{0-24}=1.822$ mcg·hr/mL for the 1 to 5-year-old group and were $C_{\text{max}}=0.383$ mcg/mL, $T_{\text{max}}=2.4$ hr, and AUC$_{0-24}=3.109$ mcg·hr/mL for the 5 to 15-year-old group.

In another study, 33 pediatric patients received doses of 12 mg/kg/day (maximum daily dose 500 mg) for 5 days, of whom 31 patients were evaluated for azithromycin pharmacokinetics following a low fat breakfast. In this study, azithromycin concentrations were determined over a 24 hr period following the last daily dose. Patients weighing above 41.7 kg received the maximum adult daily dose of 500 mg. Seventeen patients (weighing 41.7 kg or less) received a total dose of 60 mg/kg. The following table shows pharmacokinetic data in the subset of pediatric patients who received a total dose of 60 mg/kg.

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter [mean (SD)]</th>
<th>5-Day Regimen (12 mg/kg for 5 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>17</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (mcg/mL)</td>
<td>0.5 (0.4)</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (hr)</td>
<td>2.2 (0.8)</td>
</tr>
<tr>
<td>AUC$_{0-24}$ (mcg·hr/mL)</td>
<td>3.9 (1.9)</td>
</tr>
</tbody>
</table>

Single dose pharmacokinetics of azithromycin in pediatric patients given doses of 30 mg/kg have not been studied. [see Dosage and Administration (2)]

Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered. The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1 and the effects of other drugs on the pharmacokinetics of azithromycin are shown in Table 2.
Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 1. No dosage adjustment of drugs listed in Table 1 is recommended when co-administered with azithromycin.

Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C\textsubscript{max} and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 2. [see Drug Interactions (7.3)]

**Table 1. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin**

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Dose of Co-administered Drug</th>
<th>Dose of Azithromycin</th>
<th>n</th>
<th>Ratio (with/without azithromycin) of Co-administered Drug Pharmacokinetic Parameters (90% CI); No Effect = 1.00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean C\textsubscript{max}</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>10 mg/day for 8 days</td>
<td>500 mg/day orally on days 6–8</td>
<td>12</td>
<td>0.83 (0.63 to 1.08)</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>200 mg/day for 2 days, then 200 mg twice a day for 18 days</td>
<td>500 mg/day orally for days 16–18</td>
<td>7</td>
<td>0.97 (0.88 to 1.06)</td>
</tr>
<tr>
<td>Cetirizine</td>
<td>20 mg/day for 11 days</td>
<td>500 mg orally on day 7, then 250 mg/day on days 8–11</td>
<td>14</td>
<td>1.03 (0.93 to 1.14)</td>
</tr>
<tr>
<td>Didanosine</td>
<td>200 mg orally twice a day for 21 days</td>
<td>1200 mg/day orally on days 8–21</td>
<td>6</td>
<td>1.44 (0.85 to 2.43)</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>400 mg/day for 7 days</td>
<td>600 mg orally on day 7</td>
<td>14</td>
<td>1.04* (0.98 to 1.11)</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>200 mg orally single dose</td>
<td>1200 mg orally single dose</td>
<td>18</td>
<td>1.04 (0.86 to 1.08)</td>
</tr>
<tr>
<td>Indinavir</td>
<td>800 mg three times a day for 5 days</td>
<td>1200 mg orally on day 5</td>
<td>18</td>
<td>0.96 (0.86 to 1.08)</td>
</tr>
<tr>
<td>Midazolam</td>
<td>15 mg orally on day 3</td>
<td>500 mg/day orally for 3 days</td>
<td>12</td>
<td>1.27 (0.89 to 1.81)</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>750 mg three times a day for 11 days</td>
<td>1,200 mg orally on day 9</td>
<td>14</td>
<td>0.90 (0.81 to 1.01)</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>100 mg on days 1 and 4</td>
<td>500 mg/day orally for 3 days</td>
<td>12</td>
<td>1.16 (0.86 to 1.57)</td>
</tr>
<tr>
<td>Theophylline</td>
<td>4 mg/kg IV on days 1, 11, 25</td>
<td>500 mg orally on day 7, 250 mg/day on days 8–11</td>
<td>10</td>
<td>1.19 (1.02 to 1.40)</td>
</tr>
<tr>
<td>Theophylline</td>
<td>300 mg orally twice a day for 15 days</td>
<td>500 mg orally on day 6, then 250 mg/day on days 7–10</td>
<td>8</td>
<td>1.09 (0.92 to 1.29)</td>
</tr>
<tr>
<td>Triazolam</td>
<td>0.125 mg on day 2</td>
<td>500 mg orally on day 1, then 250 mg/day on day 2</td>
<td>12</td>
<td>1.06* (0.85 to 1.32)</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>160 mg/800</td>
<td></td>
<td></td>
<td>0.84 (0.75 to 0.94)</td>
</tr>
</tbody>
</table>
Trimethoprim/Sulfamethoxazole
mg/day orally for 7 days
1200 mg orally on day 7
12

Zidovudine
500 mg/day orally for 21 days
600 mg/day orally for 14 days
5

Zidovudine
500 mg/day orally for 21 days
1200 mg/day orally for 14 days
4

<table>
<thead>
<tr>
<th>Co-administered Drug</th>
<th>Dose of Co-administered Drug</th>
<th>Dose of Azithromycin</th>
<th>n</th>
<th>Ratio (with/without co-administered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); No Effect = 1.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efavirenz</td>
<td>400 mg/day for 7 days</td>
<td>600 mg orally on day 7</td>
<td>14</td>
<td>1.22 (1.04 to 1.42)</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>200 mg orally single dose</td>
<td>1,200 mg orally single dose</td>
<td>18</td>
<td>0.82 (0.66 to 1.02)</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>750 mg three times a day for 11 days</td>
<td>1,200 mg orally on day 9</td>
<td>14</td>
<td>2.36 (1.77 to 3.15)</td>
</tr>
</tbody>
</table>

* - 90% Confidence interval not reported

12.4 Microbiology

Mechanism of Action
Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.

Resistance
Azithromycin demonstrates cross resistance with erythromycin. The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation. Ribosomal modifications can determine cross resistance to other macrolides, lincosamides, and streptogramin B (MLS\textsubscript{B} phenotype).

Antimicrobial Activity
Azithromycin has been shown to be active against most isolates of the following microorganisms, both \textit{in vitro} and in clinical infections. [see Indications and Usage (1)]

Gram-Positive Bacteria

* \textit{Staphylococcus aureus}*
* \textit{Streptococcus agalactiae}*
* \textit{Streptococcus pneumoniae}*
* \textit{Streptococcus pyogenes}*

Gram-Negative Bacteria
Other Bacteria

*Chlamydophila pneumoniae*
*Chlamydia trachomatis*
*Mycoplasma pneumoniae*

The following *in vitro* data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an *in vitro* minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for azithromycin against isolates of similar genus or organism group. However, the efficacy of azithromycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.

Gram-Positive Bacteria

Beta-hemolytic streptococci (Groups C, F, G)
Viridans group streptococci

Gram-Negative Bacteria

*Bordetella pertussis*
*Legionella pneumophila*

Anaerobic Bacteria

*Prevotella bivia*
*Peptostreptococcus species*

Other Bacteria

*Ureaplasma urealyticum*

**Susceptibility Testing**

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. No evidence of impaired fertility due to azithromycin was found in rats given daily doses up to 10 mg/kg (approximately 0.2 times an adult daily dose of 500 mg based on body surface area).

#### 13.2 Animal Toxicology and/or Pharmacology

Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice,
rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis of body surface area, are similar to or less than the highest recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (50 mg/kg/day dose) at the observed maximal plasma concentration of 1.3 mcg/mL (1.6 times the observed C\text{max} of 0.821 mcg/mL at the adult dose of 2 g). Similarly, it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum concentration of 1 mcg/mL (1.2 times the observed C\text{max} of 0.821 mcg/mL at the adult dose of 2 g). Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day, which is less than the pediatric dose of 60 mg/kg based on the surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean maximal serum concentrations of 1.86 mcg/mL, approximately 1.5 times the C\text{max} of 1.27 mcg/mL at the pediatric dose. Phospholipidosis has been observed in neonatal dogs (10 mg/kg/day) at maximum mean whole blood concentrations of 3.54 mcg/mL, approximately 3 times the pediatric dose C\text{max}. The significance of these findings for animals and for humans is unknown.

14 CLINICAL STUDIES

14.1 Adult Patients

Acute Bacterial Exacerbations of Chronic Bronchitis

In a randomized, double-blind controlled clinical trial of acute exacerbation of chronic bronchitis (AECB), azithromycin (500 mg once daily for 3 days) was compared with clarithromycin (500 mg twice daily for 10 days). The primary endpoint of this trial was the clinical cure rate at Days 21–24. For the 304 patients analyzed in the modified intent-to-treat analysis at the Days 21–24 visit, the clinical cure rate for 3 days of azithromycin was 85% (125/147) compared to 82% (129/157) for 10 days of clarithromycin.

The following outcomes were the clinical cure rates at the Days 21–24 visit for the bacteriologically evaluable patients by pathogen:

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Azithromycin (3 Days)</th>
<th>Clarithromycin (10 Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>29/32 (91%)</td>
<td>21/27 (78%)</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>12/14 (86%)</td>
<td>14/16 (88%)</td>
</tr>
<tr>
<td>M. catarrhalis</td>
<td>11/12 (92%)</td>
<td>12/15 (80%)</td>
</tr>
</tbody>
</table>

Acute Bacterial Sinusitis

In a randomized, double-blind, double-dummy controlled clinical trial of acute bacterial sinusitis, azithromycin (500 mg once daily for 3 days) was compared with amoxicillin/clavulanate (500/125 mg three times a day for 10 days). Clinical response assessments were made at Day 10 and Day 28. The primary endpoint of this trial was prospectively defined as the clinical cure rate at Day 28. For the 594 patients analyzed in the modified intent to treat analysis at the Day 10 visit, the clinical cure rate for 3 days of azithromycin was 88% (268/303) compared to 85% (248/291) for 10 days of amoxicillin/clavulanate. For the 586 patients analyzed in the modified intent to treat analysis at the Day 28 visit, the clinical cure rate for 3 days of azithromycin was 71.5% (213/298) compared to 71.5% (206/288), with a 97.5% confidence interval of −8.4 to 8.3, for 10 days of amoxicillin/clavulanate.

In an open label, non-comparative study requiring baseline transantral sinus punctures, the following outcomes were the clinical success rates at the Day 7 and Day 28 visits for the modified intent to treat patients administered 500 mg of azithromycin once daily for 3 days with the following pathogens:

Clinical Success Rates of Azithromycin (500 mg per day for 3 Days)
14.2 Pediatric Patients

From the perspective of evaluating pediatric clinical trials, Days 11–14 were considered on-therapy evaluations because of the extended half-life of azithromycin. Days 11–14 data are provided for clinical guidance. Days 24–32 evaluations were considered the primary test of cure endpoint.

**Pharyngitis/Tonsillitis**

In three double-blind controlled studies, conducted in the United States, azithromycin (12 mg/kg once a day for 5 days) was compared to penicillin V (250 mg three times a day for 10 days) in the treatment of pharyngitis due to documented Group A β-hemolytic streptococci (GABHS or *S. pyogenes*). Azithromycin was clinically and microbiologically statistically superior to penicillin at Day 14 and Day 30 with the following clinical success (i.e., cure and improvement) and bacteriologic efficacy rates (for the combined evaluable patient with documented GABHS):

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Day 7</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. pneumoniae</em></td>
<td>23/26 (88%)</td>
<td>21/25 (84%)</td>
</tr>
<tr>
<td><em>H. influenzae</em></td>
<td>28/32 (87%)</td>
<td>24/32 (75%)</td>
</tr>
<tr>
<td><em>M. catarrhalis</em></td>
<td>14/15 (93%)</td>
<td>13/15 (87%)</td>
</tr>
</tbody>
</table>

**Three U.S. Streptococcal Pharyngitis Studies Azithromycin vs. Penicillin V EFFICACY RESULTS**

<table>
<thead>
<tr>
<th></th>
<th>Day 14</th>
<th>Day 30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacteriologic Eradication:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azithromycin</td>
<td>323/340 (95%)</td>
<td>255/330 (77%)</td>
</tr>
<tr>
<td>Penicillin V</td>
<td>242/332 (73%)</td>
<td>206/325 (63%)</td>
</tr>
<tr>
<td><strong>Clinical Success (cure plus improvement):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azithromycin</td>
<td>336/343 (98%)</td>
<td>310/330 (94%)</td>
</tr>
<tr>
<td>Penicillin V</td>
<td>284/338 (84%)</td>
<td>241/325 (74%)</td>
</tr>
</tbody>
</table>

Approximately 1% of azithromycin-susceptible *S. pyogenes* isolates were resistant to azithromycin following therapy.

**Acute Otitis Media**

Efficacy using azithromycin given over 5 days (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5).

**Trial 1**

In a double-blind, controlled clinical study of acute otitis media performed in the United States, azithromycin (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5) was compared to amoxicillin/clavulanate potassium (4:1). For the 553 patients who were evaluated for clinical efficacy, the clinical success rate (i.e., cure plus improvement) at the Day 11 visit was 88% for azithromycin and 88% for the control agent. For the 521 patients who were evaluated at the Day 30 visit, the clinical success rate was 73% for azithromycin and 71% for the control agent.

**Trial 2**

In a non-comparative clinical and microbiologic trial performed in the United States, where significant rates of beta-lactamase producing organisms (35%) were found, 131 patients were evaluable for clinical efficacy. The combined clinical success rate (i.e., cure and improvement) at the Day 11 visit was 84% for azithromycin. For the 122 patients who were evaluated at the Day 30 visit, the clinical success rate was 70% for azithromycin.

Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. The following clinical success rates were obtained from the evaluable group:
<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Day 11</th>
<th>Day 30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Azithromycin</td>
<td>Azithromycin</td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>61/74 (82%)</td>
<td>40/56 (71%)</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>43/54 (80%)</td>
<td>30/47 (64%)</td>
</tr>
<tr>
<td>M. catarrhalis</td>
<td>28/35 (80%)</td>
<td>19/26 (73%)</td>
</tr>
<tr>
<td>S. pyogenes</td>
<td>11/11 (100%)</td>
<td>7/7 (100%)</td>
</tr>
<tr>
<td>Overall</td>
<td>177/217 (82%)</td>
<td>97/137 (73%)</td>
</tr>
</tbody>
</table>

**Trial 3**

In another controlled comparative clinical and microbiologic study of otitis media performed in the United States, azithromycin (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5) was compared to amoxicillin/clavulanate potassium (4:1). This study utilized two of the same investigators as Protocol 2 (above), and these two investigators enrolled 90% of the patients in Protocol 3. For this reason, Protocol 3 was not considered to be an independent study. Significant rates of beta-lactamase producing organisms (20%) were found. Ninety-two (92) patients were evaluable for clinical and microbiologic efficacy. The combined clinical success rate (i.e., cure and improvement) of those patients with a baseline pathogen at the Day 11 visit was 88% for azithromycin vs. 100% for control; at the Day 30 visit, the clinical success rate was 82% for azithromycin vs. 80% for control.

Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. At the Day 11 and Day 30 visits, the following clinical success rates were obtained from the evaluable group:

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Day 11</th>
<th>Day 30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Azithromycin</td>
<td>Control</td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>25/29 (86%)</td>
<td>26/26 (100%)</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>9/11 (82%)</td>
<td>9/9 (100%)</td>
</tr>
<tr>
<td>M. catarrhalis</td>
<td>7/7 (100%)</td>
<td>5/5 (100%)</td>
</tr>
<tr>
<td>S. pyogenes</td>
<td>2/2 (100%)</td>
<td>5/5 (100%)</td>
</tr>
<tr>
<td>Overall</td>
<td>43/49 (88%)</td>
<td>45/45 (100%)</td>
</tr>
</tbody>
</table>

**Efficacy using azithromycin given over 3 days (10 mg/kg/day).**

**Trial 4**

In a double-blind, controlled, randomized clinical study of acute otitis media in pediatric patients from 6 months to 12 years of age, azithromycin (10 mg/kg per day for 3 days) was compared to amoxicillin/clavulanate potassium (7:1) in divided doses q12h for 10 days. Each patient received active drug and placebo matched for the comparator.

For the 366 patients who were evaluated for clinical efficacy at the Day 12 visit, the clinical success rate (i.e., cure plus improvement) was 83% for azithromycin and 88% for the control agent. For the 362 patients who were evaluated at the Days 24–28 visit, the clinical success rate was 74% for azithromycin and 69% for the control agent.

**Efficacy using azithromycin 30 mg/kg given as a single dose**

**Trial 5**

A double-blind, controlled, randomized trial was performed at nine clinical centers. Pediatric patients from 6 months to 12 years of age were randomized 1:1 to treatment with either azithromycin (given at 30 mg/kg as a single dose on Day 1) or amoxicillin/clavulanate potassium (7:1), divided q12h for 10 days.
Each child received active drug, and placebo matched for the comparator. Clinical response (Cure, Improvement, Failure) was evaluated at End of Therapy (Days 12–16) and Test of Cure (Days 28–32). Safety was evaluated throughout the trial for all treated subjects. For the 321 subjects who were evaluated at End of Treatment, the clinical success rate (cure plus improvement) was 87% for azithromycin, and 88% for the comparator. For the 305 subjects who were evaluated at Test of Cure, the clinical success rate was 75% for both azithromycin and the comparator.

**Trial 6**

In a non-comparative clinical and microbiological trial, 248 patients from 6 months to 12 years of age with documented acute otitis media were dosed with a single oral dose of azithromycin (30 mg/kg on Day 1).

For the 240 patients who were evaluable for clinical modified Intent-to-Treat (MITT) analysis, the clinical success rate (i.e., cure plus improvement) at Day 10 was 89% and for the 242 patients evaluable at Days 24–28, the clinical success rate (cure) was 85%.

<table>
<thead>
<tr>
<th>Presumed Bacteriologic Eradication</th>
<th>Day 10</th>
<th>Days 24–28</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>70/76 (92%)</td>
<td>67/76 (88%)</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>30/42 (71%)</td>
<td>28/44 (64%)</td>
</tr>
<tr>
<td>M. catarrhalis</td>
<td>10/10 (100%)</td>
<td>10/10 (100%)</td>
</tr>
<tr>
<td>Overall</td>
<td>110/128 (86%)</td>
<td>105/130 (81%)</td>
</tr>
</tbody>
</table>

**16 HOW SUPPLIED/STORAGE AND HANDLING**

ZITHROMAX is supplied in the following strengths and package configurations:

<table>
<thead>
<tr>
<th>Tablet strength</th>
<th>Tablet Color/Shape</th>
<th>Tablet Markings</th>
<th>Package Size</th>
<th>NDC Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 mg</td>
<td>Pink modified</td>
<td>Engraved with</td>
<td>Bottles of 30</td>
<td>NDC 0069-3060-</td>
</tr>
<tr>
<td>(containing      capsular shaped,</td>
<td>&quot;PFIZER&quot; on one</td>
<td>Boxes of 3 (Z-</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>azithromycin    engraved, film-</td>
<td>side and &quot;306&quot; on</td>
<td>PAKS® of 6)</td>
<td>NDC 0069-3060-</td>
<td></td>
</tr>
<tr>
<td>dihydrate       coated)</td>
<td>the other</td>
<td>Unit Dose</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>equivalent to</td>
<td></td>
<td>package of 50</td>
<td>NDC 0069-3060-</td>
<td></td>
</tr>
<tr>
<td>250 mg of</td>
<td></td>
<td></td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>azithromycin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 mg</td>
<td>Pink modified</td>
<td>Engraved with</td>
<td>Bottles of 30</td>
<td>NDC 0069-4061-</td>
</tr>
<tr>
<td>(containing      capsular shaped,</td>
<td>&quot;PFIZER&quot; on one</td>
<td>Boxes of 3 (Z-</td>
<td>01</td>
<td></td>
</tr>
<tr>
<td>azithromycin    engraved, film-</td>
<td>side and &quot;ZTM 250&quot;</td>
<td>PAKS® of 6)</td>
<td>NDC 0069-4061-</td>
<td></td>
</tr>
<tr>
<td>dihydrate       coated)</td>
<td>on the other</td>
<td>Unit Dose</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>equivalent to</td>
<td></td>
<td>package of 50</td>
<td>NDC 0069-4061-</td>
<td></td>
</tr>
<tr>
<td>500 mg of</td>
<td></td>
<td></td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>azithromycin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ZITHROMAX tablets should be stored between 15° to 30°C (59° to 86°F).
ZITHROMAX for oral suspension after constitution contains a flavored suspension. ZITHROMAX for oral suspension is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles as follows:

<table>
<thead>
<tr>
<th>Azithromycin contents per bottle</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>300 mg</td>
<td>0069-3110-19</td>
</tr>
<tr>
<td>600 mg</td>
<td>0069-3120-19</td>
</tr>
<tr>
<td>900 mg</td>
<td>0069-3130-19</td>
</tr>
<tr>
<td>1200 mg</td>
<td>0069-3140-19</td>
</tr>
</tbody>
</table>

[see Dosage and Administration (2)] for constitution instructions with each bottle type.

Storage: Store dry powder below 30°C (86°F). Store constituted suspension between 5° to 30°C (41° to 86°F) and discard when full dosing is completed.

17 PATIENT COUNSELING INFORMATION

General Patient Counseling

ZITHROMAX tablets and oral suspension can be taken with or without food.

Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and azithromycin simultaneously.

The patient should be directed to discontinue azithromycin immediately and contact a physician if any signs of an allergic reaction occur.

Direct parents or caregivers to contact their physician if vomiting and irritability with feeding occurs in the infant.

Patients should be counseled that antibacterial drugs including ZITHROMAX (azithromycin) should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When ZITHROMAX (azithromycin) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed.Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ZITHROMAX (azithromycin) or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.

See FDA-approved Patient Labeling

Rx only

Licensed from Pliva
This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com

Distributed by

Pfizer Labs
Division of Pfizer Inc, NY, NY 10017
Patient Information

ZITHROMAX® (Zith-roe-maks)
(azithromycin)
Tablets

ZITHROMAX®
(azithromycin)
Oral Suspension

Read this Patient Information leaflet before you start taking ZITHROMAX and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is ZITHROMAX?

ZITHROMAX is a macrolide antibiotic prescription medicine used in adults 18 years or older to treat certain infections caused by certain germs called bacteria. These bacterial infections include:

- acute worsening of chronic bronchitis
- acute sinus infection
- community-acquired pneumonia
- infected throat or tonsils
- skin infections
- infections of the urethra or cervix
- genital ulcers in men

ZITHROMAX is also used in children to treat:

- ear infections
- community-acquired pneumonia
- infected throat or tonsils

Azithromycin should not be taken by people who cannot tolerate oral medications because they are very ill or have certain other risk factors including:

- have cystic fibrosis
- have hospital acquired infections
- have known or suspected bacteria in the blood
- need to be in the hospital
- are elderly
- have any medical problems that can lower the ability of the immune system to fight infections

ZITHROMAX is not for viral infections such as the common cold.

It is not known if ZITHROMAX is safe and effective for genital ulcers in women.

It is not known if ZITHROMAX is safe and effective for children with ear infections, sinus infections, and community-acquired pneumonia under 6 months of age.

It is not known if ZITHROMAX is safe and effective for infected throat or tonsils in children under 2 years of age.

Who should not take ZITHROMAX?

Do not take ZITHROMAX if you:

- have had a severe allergic reaction to certain antibiotics known as macrolides or ketolides including azithromycin and erythromycin.
• have a history of cholestatic jaundice or hepatic dysfunction that happened with the use of azithromycin.

What should I tell my healthcare provider before taking ZITHROMAX?

Before you take ZITHROMAX, tell your healthcare provider if you:
• have pneumonia
• have cystic fibrosis
• have known or suspected bacteremia (bacterial infection in the blood)
• have liver or kidney problems
• have an irregular heartbeat, especially a problem called "QT prolongation"
• have a problem that causes muscle weakness (myasthenia gravis)
• have any other medical problems
• are pregnant or plan to become pregnant. It is not known if ZITHROMAX will harm your unborn baby.
• are breastfeeding or plan to breastfeed. ZITHROMAX has been reported to pass into breast milk. Talk to your healthcare provider about the best way to feed your baby while you take ZITHROMAX.

Contact your healthcare provider immediately if you are giving ZITHROMAX to a young child (less than 6 weeks of age) and he or she vomits or becomes irritable when fed.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

ZITHROMAX and other medicines may affect each other causing side effects. ZITHROMAX may affect the way other medicines work, and other medicines may affect how ZITHROMAX works.

Especially tell your healthcare provider if you take:
• nelfinavir
• a blood thinner (warfarin)
• digoxin
• phenytoin
• an antacid that contains aluminum or magnesium

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I take ZITHROMAX?
• Take ZITHROMAX exactly as your healthcare provider tells you to take it.
• ZITHROMAX can be taken with or without food.
• If you take ZITHROMAX Oral Suspension, shake the bottle well just before you take it.
• Do not skip any doses of ZITHROMAX or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless you have a serious allergic reaction or your healthcare provider tells you to stop taking ZITHROMAX. "See What are the possible side effects of ZITHROMAX?" If you skip doses, or do not complete the total course of ZITHROMAX your treatment may not work as well and your infection may be harder to treat. Taking all of your ZITHROMAX doses will help lower the chance that the bacteria will become resistant to ZITHROMAX.
• If the bacteria becomes resistant to ZITHROMAX, ZITHROMAX and other antibiotic medicines may not work for you in the future.
• If you take too much ZITHROMAX, call your healthcare provider or get medical help right away.

What are the possible side effects of ZITHROMAX?
ZITHROMAX can cause serious side effects, including:

- **Serious allergic reactions.** Allergic reactions can happen in people taking azithromycin, the active ingredient in ZITHROMAX, even after only 1 dose. Stop taking ZITHROMAX and get emergency medical help right away if you have any of the following symptoms of a severe allergic reaction:
  - trouble breathing or swallowing
  - swelling of the lips, tongue, face
  - throat tightness, hoarseness
  - rapid heartbeat
  - faintness
  - skin rash (hives)
  - new onset of fever and swollen lymph nodes

Stop taking ZITHROMAX at the first sign of a skin rash and call your healthcare provider. Skin rash may be a sign of a more serious reaction to ZITHROMAX.

- **Liver damage (hepatotoxicity).** Hepatotoxicity can happen in people who take ZITHROMAX. Call your healthcare provider right away if you have unexplained symptoms such as:
  - nausea or vomiting
  - stomach pain
  - fever
  - weakness
  - abdominal pain or tenderness
  - itching
  - unusual tiredness
  - loss of appetite
  - change in the color of your bowel movements
  - dark colored urine
  - yellowing of your skin or of the whites of your eyes

Stop taking ZITHROMAX and tell your healthcare provider right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to ZITHROMAX (a liver problem).

- **Serious heart rhythm changes (QT prolongation and torsades de pointes).** Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel faint and dizzy. ZITHROMAX may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people:
  - who are elderly
  - with a family history of prolonged QT interval
  - with low blood potassium
  - who take certain medicines to control heart rhythm (antiarrhythmics)

- **Worsening of myasthenia gravis (a problem that causes muscle weakness).** Certain antibiotics like ZITHROMAX may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Call your healthcare provider right away if you have any worsening muscle weakness or breathing problems.

- **Diarrhea.** Tell your healthcare provider right away if you have watery diarrhea, diarrhea that does not go away, or bloody stools. You may experience cramping and a fever. This could happen after you have finished your ZITHROMAX.

The most common side effects of ZITHROMAX include:
- nausea
- stomach pain
- vomiting

These are not all the possible side effects of ZITHROMAX. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-
How should I store ZITHROMAX?

- Store ZITHROMAX Tablets at 59°F to 86°F (15°C to 30°C).
- Store ZITHROMAX Oral Suspension at 41°F to 86°F (5°C to 30°C).
- Keep ZITHROMAX Oral Suspension in a tightly closed container.
- Safely throw away any medicine that is out of date or no longer needed.

Keep ZITHROMAX and all medicines out of the reach of children.

General information about the safe and effective use of ZITHROMAX.

Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use ZITHROMAX for a condition for which it was not prescribed.

Do not give ZITHROMAX to other people, even if they have the same symptoms you have.

It may harm them.

This Patient Information leaflet summarizes the most important information about ZITHROMAX. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about ZITHROMAX that is written for health professionals.

For more information, go to www.zithromax.com or call 1-800-438-1986.

What are the ingredients in ZITHROMAX Tablets and Oral Suspension?

ZITHROMAX Tablets and Oral Suspension

Active ingredient: azithromycin dehydrate

ZITHROMAX Tablets:

Inactive ingredients: dibasic calcium phosphate anhydrous, pregelatinized starch, sodium croscarmellose, magnesium stearate, sodium lauryl sulfate, hypromellose, lactose, titanium dioxide, triacetin, and D&C Red #30 aluminum lake.

ZITHROMAX Oral Suspension:

Inactive ingredients: sucrose; sodium phosphate, tribasic, anhydrous; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and spray dried artificial cherry, creme de vanilla, and banana flavors.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Distributed by

Pfizer Labs
Division of Pfizer Inc, NY, NY 10017

LAB-0372-5.0
Revised February 2017

PRINCIPAL DISPLAY PANEL - 250 mg - 30 Tablet Bottle Label

NDC 0069-3060-30

Pfizer

Zithromax®

(azithromycin) tablets

250 mg*

30 Tablets
PRINCIPAL DISPLAY PANEL - 250 mg - 6 ct. Blister Pack

Zithromax®
(AZITHROMYCIN)
250 mg*
Tablets

Costs less
than most
brand name
antibiotics†

Z
Z-PAK®
A full course
of antibiotic
therapy in
5 daily doses
Rx only
6 TABLETS
Zithromax®
(azithromycin) Tablet

250 mg

Distributed by
PFIZER LABS
Zithromax®
(AZITHROMYCIN) 250 mg*
Tablets
Costs less than most brand name antibiotics†

NDC 0069-3060-75

Z-PAK®

A full course of antibiotic therapy in 5 daily doses

Rx only

3 CARDS x 6 TABLETS

---

PRINCIPAL DISPLAY PANEL - 250 mg Tablet Blister Pack Box

UNIT DOSE

NDC 0069-3060-86

Pfizer

Zithromax®

(azithromycin) tablets

250 mg*

For in-institution use only

50 Tablets

Rx only
PRINCIPAL DISPLAY PANEL - 500 mg - 30 Tablet Bottle Label

NDC 0069-3070-30

Pfizer

Zithromax®
(azithromycin) tablets

500 mg*

30 Tablets

Rx only
PRINCIPAL DISPLAY PANEL - 500 mg - 3 ct. Tablet Blister Pack

Rx only

Z

Zithromax®
(AZITHROMYCIN) 500 mg Tablets

TRI-PAK™

3 tablets x 500 mg*

A full course of antibiotic therapy in
3 DAILY DOSES
Zithromax®
(AZITHROMYCIN) 500 mg Tablets
TRI-PAK™
3 Cards x Three 500 mg* Tablets

PRINCIPAL DISPLAY PANEL - 500 mg - 3 ct. Tablet Blister Carton
NDC 0069-3070-75

Zithromax is an oral antibiotic that is taken once a day for 3 days.

- Take 1 tablet a day for 3 days.
- Zithromax tablets can be taken with or without food.
- Be sure to finish your medication, because if you stop too soon your infection may return.

The most common side effects of Zithromax are diarrhea (4-9%), nausea (3%), and stomach pain (2-3%).

Less than 1% of patients stopped taking this drug due to side effects.

While allergic reactions to this drug are rare, should one occur, stop taking this drug and call your healthcare provider right away.

If you have any questions about this drug or its possible side effects, please talk with your healthcare provider.

NON VARNISH AREA

A full course of antibiotic therapy in 3 DAILY DOSES
Zithromax® (Azithromycin) 500 mg Tablets

TRI-PAK™

3 Cards x Three 500 mg Tablets

NDC 0069-3070-75

*Each tablet contains azithromycin dihydrate equivalent to 500 mg of azithromycin.

DOSAGE AND USE: See accompanying prescribing information.

RECOMMENDED STORAGE: Store between 15°C to 30°C (59°F to 86°F).

Please see full prescribing information enclosed.
PRINCIPAL DISPLAY PANEL - 500 mg -10 ct. Blister Card

Zithromax®
(azithromycin) Tablet

500 mg

PFIZER LABS
DIV OF PFIZER INC, NY, NY 10017
PRINCIPAL DISPLAY PANEL - 500 mg Tablet Blister Pack Box

UNIT DOSE
NDC 0069-3070-86

Pfizer
Zithromax®
(azithromycin) tablets

500 mg*
For in-institution use only
50 Tablets
Rx only
PRINCIPAL DISPLAY PANEL - 300 mg Bottle Label

NDC 0069-3110-19

300 mg (15 mL when mixed)

Zithromax®
(azithromycin for oral suspension)

CHERRY FLAVORED

100 mg* per 5 mL

Pfizer
Pfizer Labs
Division of Pfizer Inc, NY, NY 10017
PRINCIPAL DISPLAY PANEL - 300 mg Bottle Carton

NDC 0069-3110-19

300 mg (15 mL when mixed)

www.zithromax.com

Zithromax®
(azithromycin for oral suspension)

Cherry Flavored

Rx only

100 mg* per 5 mL
PRINCIPAL DISPLAY PANEL - 600 mg Bottle Label

NDC 0069-3120-19

600 mg (15 mL when mixed)

Zithromax®
(azithromycin for oral suspension)

CHERRY FLAVORED

200 mg* per 5 mL
FOR ORAL USE ONLY.
Store dry powder below 30°C (86°F).
PROTECT FROM FREEZING.

DOSEAGE AND USE
See accompanying prescribing information.

MIXING DIRECTIONS:
Tap bottle to loosen powder.
Add 9 mL of water to the bottle.
After mixing, store suspension at 5° to 30°C (41° to 86°F).
Oversized bottle provides extra space for shaking.
After mixing, use within 10 days.
Discard after full dosage is completed.
SHAKE WELL BEFORE USING.
Contains 600 mg azithromycin.

PRINCIPAL DISPLAY PANEL - 600 mg Bottle Carton
NDC 0069-3120-19
600 mg (15 mL when mixed)
www.zithromax.com

Zithromax®
(azithromycin for oral suspension)

Cherry Flavored
Rx only
200 mg* per 5 mL
PRINCIPAL DISPLAY PANEL - 900 mg Bottle Label

NDC 0069-3130-19

900 mg (22.5 mL when mixed)

Zithromax®
(azithromycin for oral suspension)

CHERRY FLAVORED

200 mg* per 5 mL
PRINCIPAL DISPLAY PANEL - 900 mg Bottle Carton

NDC 0069-3130-19

900 mg (22.5 mL when mixed)

www.zithromax.com

Zithromax®
(azithromycin for oral suspension)

Cherry Flavored

Rx only

200 mg* per 5 mL
PRINCIPAL DISPLAY PANEL - 1200 mg Bottle Label

NDC 0069-3140-19

1200 mg (30 mL when mixed)

Zithromax®
(azithromycin for oral suspension)

CHERRY FLAVORED

200 mg* per 5 mL
PRINCIPAL DISPLAY PANEL - 1200 mg Bottle Carton

NDC 0069-3140-19

1200 mg (30 mL when mixed)

www.zithromax.com

Zithromax®
(azithromycin for oral suspension)

Cherry Flavored

Rx only

200 mg* per 5 mL
# ZITHROMAX
azithromycin dihydrate tablet, film coated

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC: 0069-3060</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety
**Ingredient Name**  | **Basis of Strength**  | **Strength**  
AZITHROMYCIN DIHYDRATE (UNII: 5FD1131I7S) (AZITHROMYCIN ANHYDROUS - UNII:J2KLZ20U1M)  | AZITHROMYCIN ANHYDROUS  | 250 mg

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)</td>
<td></td>
</tr>
<tr>
<td>CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)</td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM STEARATE (UNII: 70097M6E0)</td>
<td></td>
</tr>
<tr>
<td>SODIUM LAURYL SULFATE (UNII: 368GB5141J)</td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)</td>
<td></td>
</tr>
<tr>
<td>LACTOSE, UNSPECIFIED FORM (UNII: J2B2A4N98G)</td>
<td></td>
</tr>
<tr>
<td>TITANIUM DIOXIDE (UNII: 15FDX9V2JP)</td>
<td></td>
</tr>
<tr>
<td>TRIACETIN (UNII: XHX3C3X673)</td>
<td></td>
</tr>
<tr>
<td>D&amp;C RED NO. 30 (UNII: 2S42T2808B)</td>
<td></td>
</tr>
<tr>
<td>ALUMINUM OXIDE (UNII: LMI26O6933)</td>
<td></td>
</tr>
</tbody>
</table>

### Product Characteristics

- **Color**: PINK
- **Score**: no score
- **Shape**: OVAL (modified capsular shaped)
- **Size**: 13mm
- **Flavor**: Imprint Code: PFIZER;306

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0069-3060-30</td>
<td>30 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>07/18/1996</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0069-3060-75</td>
<td>3 in 1 BOX</td>
<td>07/18/1996</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>6 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>
<td>07/18/1996</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0069-3060-86</td>
<td>50 in 1 BOX, UNIT-DOSE</td>
<td>07/18/1996</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>1 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>
<td>07/18/1996</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

- **Marketing Category**: NDA
- **Application Number or Monograph Citation**: NDA050711
- **Marketing Start Date**: 07/18/1996
- **Marketing End Date**: 07/18/1996

### ZITHROMAX

azithromycin dihydrate tablet, film coated

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:0069-3070</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
</tr>
<tr>
<td>Active Ingredient/Active Moiety</td>
<td>Ingredient Name</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>AZITHROMYCIN DIHYDRATE (UNII: 5FD1131I7S) (AZITHROMYCIN ANHYDROUS - UNII:J2KLZ20U1M)</td>
<td>AZITHROMYCIN ANHYDROUS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inactive Ingredients</th>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P921)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM STEARATE (UNII: 70097M6E30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM LAURYL SULFATE (UNII: 368GB5141J)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYPMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LACTOSE, UNSPECIFIED FORM (UNII: J2B2A4N98G)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TITANIUM DIOXIDE (UNII: 15FIX9V2JP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRIACETIN (UNII: XHX3C3X673)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D&amp;C RED NO. 30 (UNII: 2S42T2808B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALUMINUM OXIDE (UNII: LMI26O6933)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product Characteristics</th>
<th>Color</th>
<th>Score</th>
<th>Shape</th>
<th>Size</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PINK</td>
<td>no score</td>
<td>OVAL (modified capsular shaped)</td>
<td>17mm</td>
<td>PFIZER;ZTM500</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Packaging</th>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0069-3070-30</td>
<td>30 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>05/24/2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0069-3070-75</td>
<td>3 in 1 CARTON</td>
<td>05/24/2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0069-3070-86</td>
<td>3 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>
<td>05/24/2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0069-3070-86</td>
<td>50 in 1 BOX, UNIT-DOSE</td>
<td>05/24/2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0069-3070-86</td>
<td>1 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>
<td>05/24/2002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Marketing Information</th>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA050784</td>
<td>05/24/2002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ZITHROMAX**
azithromycin dihydrate powder, for suspension

<table>
<thead>
<tr>
<th>Product Information</th>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:0069-3110</td>
</tr>
</tbody>
</table>
### Route of Administration

**ORAL**

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZITHROMYCIN DIHYDRATE (UNII: 5FD1131I7S) (AZITHROMYCIN ANHYDROUS - UNII:J2KLZ20U1M)</td>
<td>AZITHROMYCIN ANHYDROUS</td>
<td>100 mg in 5 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUCROSE (UNII: C151HB554)</td>
<td></td>
</tr>
<tr>
<td>SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS (UNII: SX01TZO3QZ)</td>
<td></td>
</tr>
<tr>
<td>HYDROXYPROPYL CELLULOSE (1200000 MW) (UNII: RFW2ET671P)</td>
<td></td>
</tr>
<tr>
<td>XANTHAN GUM (UNII: TTV12P4NEE)</td>
<td></td>
</tr>
<tr>
<td>FD&amp;C RED NO. 40 (UNII: WZB9127XOA)</td>
<td></td>
</tr>
</tbody>
</table>

### Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Shape</td>
<td>Size</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Flavor</td>
<td>Imprint Code</td>
</tr>
<tr>
<td>CHERRY, VANILLA, BANANA</td>
<td></td>
</tr>
<tr>
<td>Contains</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0069-3110-19</td>
<td>1 in 1 CARTON</td>
<td>10/19/1995</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>15 mL in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA050710</td>
<td>10/19/1995</td>
<td></td>
</tr>
</tbody>
</table>

### ZITHROMAX

azithromycin dihydrate powder, for suspension

### Product Information

**Product Type**

HUMAN PRESCRIPTION DRUG

**Route of Administration**

ORAL

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZITHROMYCIN DIHYDRATE (UNII: 5FD1131I7S) (AZITHROMYCIN ANHYDROUS - UNII:J2KLZ20U1M)</td>
<td>AZITHROMYCIN ANHYDROUS</td>
<td>200 mg</td>
</tr>
</tbody>
</table>
### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUCROSE (UNII: C151H8M554)</td>
<td></td>
</tr>
<tr>
<td>SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS (UNII: SX01TZ03QZ)</td>
<td></td>
</tr>
<tr>
<td>HYDROXYPROPYL CELLULOSE (1200000 MW) (UNII: RFW2ET671P)</td>
<td></td>
</tr>
<tr>
<td>XANTHAN GUM (UNII: TTV12P4NEE)</td>
<td></td>
</tr>
<tr>
<td>FD&amp;C RED NO. 40 (UNII: WZB9127XOA)</td>
<td></td>
</tr>
</tbody>
</table>

### Product Characteristics

- **Color**:  
- **Score**:  
- **Shape**:  
- **Size**:  
- **Flavor**: CHERRY, VANILLA, BANANA  
- **Imprint Code**:  

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0069-3120-19</td>
<td>1 in 1 CARTON</td>
<td>10/19/1995</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>15 mL in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>10/19/1995</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA050710</td>
<td>10/19/1995</td>
<td></td>
</tr>
</tbody>
</table>

### ZITHROMAX

*azithromycin dihydrate powder, for suspension*

### Product Information

- **Product Type**: HUMAN PRESCRIPTION DRUG  
- **Route of Administration**: ORAL  
- **Item Code (Source)**: NDC:0069-3130

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZITHROMYCIN DIHYDRATE (UNII: 5FD1131I7S) (AZITHROMYCIN ANHYDROUS - UNII:J2KLZ20U1M)</td>
<td>AZITHROMYCIN ANHYDROUS</td>
<td>200 mg in 5 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUCROSE (UNII: C151H8M554)</td>
<td></td>
</tr>
</tbody>
</table>
**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
<th>Shape</th>
<th>Size</th>
<th>Flavor</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CHERRY, VANILLA, BANANA</td>
<td></td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0069-3130-19</td>
<td>1 in 1 CARTON</td>
<td>10/19/1995</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:0069-3140-19</td>
<td>22.5 mL in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>10/19/1995</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA050710</td>
<td>10/19/1995</td>
<td></td>
</tr>
</tbody>
</table>

**ZITHROMAX**

azithromycin dihydrate powder, for suspension

**Product Information**

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:0069-3140</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORAL</td>
</tr>
</tbody>
</table>

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZITHROMYCIN DIHYDRATE (UNII:5FD1131I7S) (AZITHROMYCIN ANHYDROUS - UNII:J2KLZ20U1M)</td>
<td>AZITHROMYCIN ANHYDROUS</td>
<td>200 mg in 5 mL</td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUCROSE (UNII: C151HB M554)</td>
<td></td>
</tr>
<tr>
<td>SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS (UNII: SX01TZ03QZ)</td>
<td></td>
</tr>
<tr>
<td>HYDROXYPROPYL CELLULOSE (1200000 MW) (UNII: RFW2ET671P)</td>
<td></td>
</tr>
<tr>
<td>XANTHAN GUM (UNII: TTV12P4NEE)</td>
<td></td>
</tr>
<tr>
<td>FD&amp;C RED NO. 40 (UNII: WZB9127XOA)</td>
<td></td>
</tr>
</tbody>
</table>
### Product Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Color</td>
<td></td>
<td>Score</td>
</tr>
<tr>
<td>Shape</td>
<td></td>
<td>Size</td>
</tr>
<tr>
<td>Flavor</td>
<td>CHERRY, VANILLA, BANANA</td>
<td>Imprint Code</td>
</tr>
<tr>
<td>Contains</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0069-3140-19</td>
<td>1 in 1 CARTON</td>
<td>10/19/1995</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>30 mL in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA050710</td>
<td>10/19/1995</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler
- Pfizer Laboratories Div Pfizer Inc (134489525)

### Registrant
- Pfizer Inc (13480771)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Ireland Pharmaceuticals</td>
<td>896090987</td>
<td>ANALYSIS(0069-3060, 0069-3070, 0069-3110, 0069-3120, 0069-3130, 0069-3140) , API MANUFACTURE(0069-3060, 0069-3070, 0069-3110, 0069-3120, 0069-3130, 0069-3140)</td>
<td></td>
</tr>
<tr>
<td>Pliva Hrvatska d.o.o.</td>
<td>500651871</td>
<td>ANALYSIS(0069-3060, 0069-3070, 0069-3110, 0069-3120, 0069-3130, 0069-3140) , API MANUFACTURE(0069-3060, 0069-3070, 0069-3110, 0069-3120, 0069-3130, 0069-3140)</td>
<td></td>
</tr>
<tr>
<td>Pfizer Asia Pacific PTE</td>
<td>994077086</td>
<td>ANALYSIS(0069-3060, 0069-3070, 0069-3110, 0069-3120, 0069-3130, 0069-3140) , API</td>
<td></td>
</tr>
</tbody>
</table>